Clinical-stage biotechnology company discovering and developing novel therapies to treat immune-mediated chronic inflammatory diseases.
Clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis.
Clinical-stage biotechnology company developing purpose-built therapeutics by leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology.
A full-service, digitally-powered pharmacy providing an easier, more supportive and more affordable pharmacy experience.
Clinical-stage company developing transformative medicines that dramatically improve the lives of patients with life-altering immune diseases.
Completed reverse merger in 2023
Commercial-stage life science company focused on manufacturing scalable single-use bioreactors and providing process development services to cell therapy clients.
Clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders.
Acquired by Incyte in 2024
Global contract development and manufacturing organization for radiotherapeutics.
Health prediction company utilizing proteomics and advanced statistical techniques to better predict and improve health outcomes.
Commercial-stage life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing.
Disruptive animal health provider delivering innovative diagnostic solutions to veterinarians and pet owners across the United States.
Clinical-stage biotechnology company focused on enabling cures with hematopoietic stem cell therapies.
Merged with Amplitude Healthcare Acquisition Corporation in 2021
Clinical-stage biotechnology company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.
Completed IPO in 2021
Clinical-stage biotechnology company pursuing the development of novel small molecules that target cancer through its dependency on stress support pathways.
Clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.
Completed IPO in 2021
Clinical-stage ophthalmic company focused on novel therapeutics to address unmet medical needs, providing for the restoration, preservation, and improvement of patient vision and quality of life.
Acquired by a strategic in 2024
Commercial-stage specialty pharmaceutical company focused on gastrointestinal, dermatological, and women’s health products.
Clinical-stage therapeutics company focused on the central nervous system (CNS), orphan diseases, and conditions with high unmet medical need.
FOR VELAN HOLDINGS PLEASE SEE OUR 13F FILINGS.